196 related articles for article (PubMed ID: 12596221)
1. Novel 3-arylamino- and 3-cycloalkylamino-5, 6-diphenyl-pyridazines active as ACAT inhibitors.
Toma L; Giovannoni MP; Vergelli C; Dal Piaz V; Kwon BM; Kim YK; Gelain A; Barlocco D
Arch Pharm (Weinheim); 2002; 335(11-12):563-6. PubMed ID: 12596221
[TBL] [Abstract][Full Text] [Related]
2. Biphenyl versus phenylpyridazine derivatives: the role of the heterocycle in a series of acyl-CoA:cholesterol acyl transferase inhibitors.
Gelain A; Barlocco D; Kwon BM; Jeong TS; Im KR; Legnani L; Toma L
J Med Chem; 2008 Mar; 51(5):1474-7. PubMed ID: 18284184
[TBL] [Abstract][Full Text] [Related]
3. 5,6-Diphenylpyridazine derivatives as acyl-CoA:cholesterol acyltransferase inhibitors.
Giovannoni MP; Piaz VD; Kwon BM; Kim MK; Kim YK; Toma L; Barlocco D; Bernini F; Canavesi M
J Med Chem; 2001 Nov; 44(24):4292-5. PubMed ID: 11708931
[TBL] [Abstract][Full Text] [Related]
4. Discovery of pyrrolopyridazines as novel DGAT1 inhibitors.
Fox BM; Iio K; Li K; Choi R; Inaba T; Jackson S; Sagawa S; Shan B; Tanaka M; Yoshida A; Kayser F
Bioorg Med Chem Lett; 2010 Oct; 20(20):6030-3. PubMed ID: 20833038
[TBL] [Abstract][Full Text] [Related]
5. Mono- or diphenylpyridazines connected to N-(2,4-difluorophenyl)-N'-heptylurea as acyl-CoA:cholesterol acyltransferase inhibitors.
Gelain A; Bettinelli I; Barlocco D; Kwon BM; Jeong TS; Cho KH; Toma L
J Med Chem; 2005 Dec; 48(24):7708-13. PubMed ID: 16302810
[TBL] [Abstract][Full Text] [Related]
6. Acyl-CoA:Cholesterol O-acyltransferase (ACAT) inhibitors. 2. 2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT.
Astles PC; Ashton MJ; Bridge AW; Harris NV; Hart TW; Parrott DP; Porter B; Riddell D; Smith C; Williams RJ
J Med Chem; 1996 Mar; 39(7):1423-32. PubMed ID: 8691472
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationship studies on a novel series of naphthylidinoylureas as inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT).
Ohnuma S; Muraoka M; Ioriya K; Ohashi N
Bioorg Med Chem Lett; 2004 Mar; 14(5):1309-11. PubMed ID: 14980688
[TBL] [Abstract][Full Text] [Related]
8. 3-heptylamino-5-phenylpyridazine derivatives as analogues of Acyl-CoA: cholesterol acyltransferase inhibitors containing the N-heptyl-N'-arylureidic moiety.
Gelain A; Barlocco D; Kwon BM; Jeong TS; Im KR; Legnani L; Toma L
Arch Pharm (Weinheim); 2006 Dec; 339(12):645-51. PubMed ID: 17109461
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of novel 4,5-diphenylthiazole derivatives as potential acyl-CoA:cholesterol O-acyltransferase inhibitors.
Romeo G; Salerno L; Milla P; Siracusa M; Cattel L; Russo F
Pharmazie; 1999 Jan; 54(1):19-23. PubMed ID: 9987793
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibitors of acyl-CoA:cholesterol acyltransferase. 2. Structure-activity relationships of novel N-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)amides.
Kataoka K; Shiota T; Takeyasu T; Minoshima T; Watanabe K; Tanaka H; Mochizuki T; Taneda K; Ota M; Tanabe H; Yamaguchi H
J Med Chem; 1996 Mar; 39(6):1262-70. PubMed ID: 8632433
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of acyl CoA:cholesterol acyltransferase.
Vaccaro W; Amore C; Berger J; Burrier R; Clader J; Davis H; Domalski M; Fevig T; Salisbury B; Sher R
J Med Chem; 1996 Apr; 39(8):1704-19. PubMed ID: 8648610
[TBL] [Abstract][Full Text] [Related]
12. Chemical modification and structure-activity relationships of pyripyropenes. 3. Synthetic conversion of pyridine-pyrone moiety.
Obata R; Sunazuka T; Tian Z; Tomoda H; Harigaya Y; Omura S
J Antibiot (Tokyo); 1997 Mar; 50(3):229-36. PubMed ID: 9127194
[TBL] [Abstract][Full Text] [Related]
13. SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors.
Zhou G; Ting PC; Aslanian R; Cao J; Kim DW; Kuang R; Lee JF; Schwerdt J; Wu H; Herr RJ; Zych AJ; Yang J; Lam S; Wainhaus S; Black TA; McNicholas PM; Xu Y; Walker SS
Bioorg Med Chem Lett; 2011 May; 21(10):2890-3. PubMed ID: 21489787
[TBL] [Abstract][Full Text] [Related]
14. Discovery and combinatorial synthesis of fungal metabolites beauveriolides, novel antiatherosclerotic agents.
Tomoda H; Doi T
Acc Chem Res; 2008 Jan; 41(1):32-9. PubMed ID: 17803269
[TBL] [Abstract][Full Text] [Related]
15. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
[TBL] [Abstract][Full Text] [Related]
16. Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon.
An S; Park YD; Paik YK; Jeong TS; Lee WS
Bioorg Med Chem Lett; 2007 Feb; 17(4):1112-6. PubMed ID: 17157006
[TBL] [Abstract][Full Text] [Related]
17. Novel 3,5-diaryl pyrazolines as human acyl-CoA:cholesterol acyltransferase inhibitors.
Jeong TS; Kim KS; An S; Cho KH; Lee S; Lee WS
Bioorg Med Chem Lett; 2004 Jun; 14(11):2715-7. PubMed ID: 15125920
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).
Léger S; Black WC; Deschenes D; Dolman S; Falgueyret JP; Gagnon M; Guiral S; Huang Z; Guay J; Leblanc Y; Li CS; Massé F; Oballa R; Zhang L
Bioorg Med Chem Lett; 2010 Jan; 20(2):499-502. PubMed ID: 20004097
[TBL] [Abstract][Full Text] [Related]
19. Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis.
Miyazaki A; Sakai M; Sakamoto Y; Horiuchi S
Curr Opin Investig Drugs; 2003 Sep; 4(9):1095-9. PubMed ID: 14582454
[TBL] [Abstract][Full Text] [Related]
20. The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors.
Ting PC; Kuang R; Wu H; Aslanian RG; Cao J; Kim DW; Lee JF; Schwerdt J; Zhou G; Wainhaus S; Black TA; Cacciapuoti A; McNicholas PM; Xu Y; Walker SS
Bioorg Med Chem Lett; 2011 Mar; 21(6):1819-22. PubMed ID: 21316223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
